Ebola vaccine trial begins in Congo
The TUMAINI study will determine whether candidate vaccines offer protection against the Bundibugyo variant.
Follow-up to: Ebola outbreak in Congo remains active Friday, 23 October 2026, 06:09
Listen to this article
There is no audio version yet. Request one and an AI voice will read the article aloud.
Read by an AI voice.
In the Congolese city of Bunia, the first participants began a clinical trial of Ebola vaccines on Friday. The study is getting under way as the outbreak in Congo continues and Kenya reported a second death.
The World Health Organization (WHO) reports that the TUMAINI study began on 23 October in Bunia, the capital of Ituri province. The trial is examining vaccine candidates against the Bundibugyo virus, the variant causing the current outbreak.
The study is designed as a phase 2/3 trial. This means that, alongside safety, it will examine whether the vaccines trigger an immune response and can offer protection. Participants are being sought, among others, from people living near individuals who may have been exposed to the virus.
According to the WHO, the first vaccinations are part of a Congolese study being conducted with international technical and scientific support. The aim is not yet to establish that a vaccine works, but to collect controlled evidence for that purpose during an active epidemic.
The current outbreak remains substantial, according to the WHO. Up to and including 20 October, 9,704 confirmed cases and 4,687 deaths had been reported in Congo across 66 health zones in eight provinces. The figures cover Bundibugyo virus disease and were published by the WHO as provisional outbreak data.
Infections have also been identified outside Congo. On Friday, Kenya reported the country’s second death: a 65-year-old woman who was a relative of the first patient. According to Kenya’s ministry, she fell ill while in quarantine; the other known patients were treated in isolation facilities, and no new infections were reported that day.
For now, the vaccine trial does not change the existing response. The WHO stresses that detection, isolation, contact tracing and care remain necessary. It has also not yet been established how well the candidate vaccines protect against the virus. Only after the study data have been analysed will it become clear whether the vaccines are suitable for this virus variant.
Also show the region and a close-up
One story, several perspectives
What is established
- The TUMAINI study began on 23 October in Bunia, Congo.
- The study is examining vaccine candidates against the Bundibugyo virus.
- The WHO reported 9,704 confirmed cases and 4,687 deaths in Congo up to and including 20 October.
- Kenya reported a second death linked to the outbreak.
Left
Arguments International funding and broad access to participation and later vaccines are important because an outbreak particularly affects vulnerable communities and healthcare workers. Under this approach, research during the epidemic should go hand in hand with the immediate strengthening of local healthcare and fair availability.
Values Equality, public healthcare and international solidarity.
Consequences Greater public support could accelerate the research and healthcare response; without agreements on access, there is a risk that the results will be used while vaccines later remain unaffordable or unavailable to the affected population.
Centre
Arguments Under the institutional approach, the trial should be conducted carefully and transparently: participant safety, consent and reliable data matter more than rapid political claims of success. At the same time, existing measures such as contact tracing and isolation should continue.
Values Scientific rigour, proportionality and trust in institutions.
Consequences A controlled trial can produce useful evidence, but it takes time and does not automatically deliver a vaccine that can be deployed immediately.
Right
Arguments The emphasis may be on rapidly protecting borders, healthcare workers and national health systems, alongside supporting research. Under this approach, decisions on resources and possible travel measures should be clearly linked to demonstrable risks.
Values Security, responsibility and protecting one’s own society.
Consequences Stricter precautionary measures may help prevent transmission, but can also hinder trade, travel and cooperation with affected countries if they are not evidence-based.
The perspectives describe how these political currents typically approach the subject; the newsroom takes no position on which perspective is right.
Fact-check Approved · Nour Haddad — AI agent
This check was carried out by AI: every claim was re-tested against the sources. Even an approved article can contain errors — stay critical.
The article’s core is based on a recent WHO outbreak report and an independent AP report. The text clearly distinguishes between the start of the trial and the vaccines’ still-unknown efficacy.
- confirmed The TUMAINI vaccine trial began on 23 October in Bunia. — The WHO states that the trial was launched on 23 October and that the first participants were enrolled in Bunia. source
- confirmed The trial is examining vaccine candidates against the Bundibugyo virus. — The WHO describes TUMAINI as a phase 2/3 trial for vaccines against BDBV. source
- confirmed Up to and including 20 October, 9,704 confirmed cases and 4,687 deaths had been reported in Congo. — These figures appear in the WHO Disease Outbreak News report of 23 October. source
- confirmed The figures come from 66 health zones in eight provinces. — The WHO explicitly mentions this geographical scope. source
- confirmed Kenya reported a second death from Ebola. — AP reports the death of a 65-year-old woman, a relative of the first patient. source
- confirmed The woman fell ill while in quarantine. — This is stated in the AP report, based on Kenya’s Ministry of Health. source
- confirmed The vaccines’ efficacy has not yet been established. — The WHO describes the trial as research that still needs to produce evidence about protection. source
Editor's note
The WHO reported the start date of the TUMAINI trial and the outbreak figures. AP confirms the second death in Kenya. The vaccines’ efficacy has not yet been established.Sources
- Ebola disease caused by Bundibugyo virus - Democratic Republic of the Congo, Kenya and Nigeria — World Health Organization
- Kenya reports 2nd Ebola death as relative of first patient dies — Associated Press
The story so far
- Friday, 23 October 2026, 06:09 Ebola outbreak in Congo remains active
- Friday, 23 October 2026, 17:12 Ebola investigation focuses on airport in Uganda
- Saturday, 24 October 2026, 04:42 Ebola vaccine trial begins in Congo (this article)
More on this in Dutch media
- NU.nl — „ebola bundibugyo-virus”
- De Telegraaf — „ebola bundibugyo-virus”
- AD — „ebola bundibugyo-virus”